
Cenobamate sNDAs target PGTC seizures in patients ≥12 years and pediatric focal seizures; phase 3 PGTC data showed a 71.9% median reduction.
Primary care physicians, including pediatricians, admit that they are not as familiar about specific aspects of epilepsy as they should be.






